-transparent.png){kind=logo}
Small amounts (10(-10) mol) of purified human chemotactic factor inactivator (CFI) suppress leukocytic infiltration, permeability changes, and hemorrhage associated with acute immune complex-induced injury in rats. The reversed passive dermal Arthus reaction and acute immune complex-induced alveolitis in rats have served as the model systems of inflammation. The mechanism of inhibition does not appear to relate to interference with formation and deposition of immune complexes, or with fixation of complement in vitro or iv vivo. Human CFI inhibits in vitro the chemotactic activity generated in complement-activated rat serum. The inhibitory effects of human CFI are not seen if it is first heat inactivated. The data provide the first direct support for the conclusion that CFI has anti-inflammatory activity.
K J Johnson, and
T P Anderson, and
P A Ward
December 1982,
The American journal of pathology,
K J Johnson, and
T P Anderson, and
P A Ward
June 1982,
Immunopharmacology,
K J Johnson, and
T P Anderson, and
P A Ward
January 1984,
Journal of experimental pathology,
K J Johnson, and
T P Anderson, and
P A Ward
April 1974,
The New England journal of medicine,
K J Johnson, and
T P Anderson, and
P A Ward
July 1979,
Inflammation,
K J Johnson, and
T P Anderson, and
P A Ward
May 1973,
The Journal of clinical investigation,
K J Johnson, and
T P Anderson, and
P A Ward
December 1982,
The American journal of pathology,
K J Johnson, and
T P Anderson, and
P A Ward
December 1985,
Infection and immunity,
K J Johnson, and
T P Anderson, and
P A Ward
January 1981,
The American journal of pathology,
K J Johnson, and
T P Anderson, and
P A Ward
July 1976,
The Journal of clinical investigation,
